Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07227077 | Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial | recruiting | N/A | 50 | Medical College of WisconsinOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07644598 | MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer(MIDAS) | recruiting | Phase 2 | 58 | Georgetown UniversityOTHER | 1 | Aug 20, 2026 |
| clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | recruiting | Phase 3 | 804 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04506567 | Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC | active not recruiting | Phase 1 | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04775355 | Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer | recruiting | — | 30 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05424783 | MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)(MAGIC) | active not recruiting | — | 222 | Northwestern UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06549036 | Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening | not yet recruiting | N/A | 228 | VA Office of Research and DevelopmentFED | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07109427 | Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System | recruiting | N/A | 40,000 | Washington University School of MedicineOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07231627 | AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions | recruiting | N/A | 50 | University of ArkansasOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07237269 | Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer | recruiting | Phase 2 | 140 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02609269 | Decipher Genomics Resource for Intelligent Discovery(GRID®) | enrolling by invitation | — | 1,000,000 | GenomeDx Biosciences CorpINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT03732820 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 17 | Aug 18, 2026 | clinicaltrials |
| NCT05471128 | MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy(OU-SCC-PROBX) | active not recruiting | — | 29 | University of OklahomaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | recruiting | Phase 1 | 60 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07052578 | Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration(CONCORD) | recruiting | — | 400 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07455058 | Water Vapor Ablation for Prostate Cancer: Long-Term Registry(VAPOR-LTR) | recruiting | — | 2,500 | Francis Medical Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07594002 | Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy | recruiting | N/A | 40 | University of KentuckyOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT01407263 | Trial of Modifications to Radical Prostatectomy | active not recruiting | Phase 3 | 3,204 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03784924 | EDRN Prostate MRI Biomarker Study(P-MRI) | recruiting | — | 950 | University of MichiganOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04134260 | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | active not recruiting | Phase 3 | 586 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | active not recruiting | Phase 3 | 2,753 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05053152 | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | active not recruiting | Phase 2 | 194 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06842498 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | recruiting | Phase 2 | 75 | Kyntra BioINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06957691 | Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy(Fezo-ADT) | recruiting | Phase 2 | 60 | Shehzad Basaria, M.D.OTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07202247 | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | recruiting | Phase 2 | 60 | City of Hope Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07615101 | Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. | recruiting | Phase 3 | 365 | Norroy Bioscience Co., LTDINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07768917 | Training on Systemic and Organ Spec. PM in PC | not yet recruiting | N/A | 20 | Massachusetts General HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07769372 | Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer | not yet recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04812366 | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer(GUNS) | recruiting | Phase 2 | 315 | University of British ColumbiaOTHER | 2 | Aug 14, 2026 | clinicaltrials |
| NCT05043012 | Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study) | recruiting | N/A | 258 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06235151 | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer(Solar-Stage) | active not recruiting | Phase 3 | 439 | Curium US LLCINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06717711 | Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers(RCT_LiESWT) | recruiting | Phase 3 | 158 | Regina Elena Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06826768 | A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC | recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07733908 | Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer | not yet recruiting | Phase 2 | 22 | Aditya BagrodiaOTHER | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07737925 | LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan | not yet recruiting | Phase 2 | 30 | Thomas Jefferson UniversityOTHER | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07765940 | Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer(COPRA424) | not yet recruiting | Phase 1 / Phase 2 | 52 | RadAlliance Therapeutics, IncINDUSTRY | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07766122 | Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU(ECETEP) | not yet recruiting | Phase 4 | 30 | University Hospital, ToulouseOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07766486 | Prospective Study on the Role of Radical Prostatectomy in Oligo-metastatic Hormone-sensitive Prostate Cancer in Patients on Androgen Deprivation Therapy(MAZINGA) | active not recruiting | N/A | 30 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07766603 | Preoperative Breathing Exercise Training and Postoperative Delirium After Robotic Radical Prostatectomy | not yet recruiting | N/A | 50 | ALİ DEMİRTAŞOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02759744 | Fusion Guided Focal Laser Ablation of Prostate Cancer | enrolling by invitation | N/A | 30 | National Institutes of Health Clinical Center (CC)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03624660 | Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer(PR11) | active not recruiting | Phase 2 | 100 | University of FloridaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05350475 | Protons vs. Photons for High-risk Prostate Cancer | active not recruiting | N/A | 102 | University of AarhusOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05519449 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | recruiting | Phase 1 | 272 | Janux TherapeuticsINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT05722288 | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers | active not recruiting | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials